| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematopoietic Stem Cell Transplantation | 148 | 2024 | 6550 | 6.330 |
Why?
|
| Graft vs Host Disease | 71 | 2024 | 2638 | 3.890 |
Why?
|
| Transplantation Conditioning | 69 | 2024 | 2238 | 3.470 |
Why?
|
| Transplantation, Homologous | 67 | 2022 | 2843 | 1.910 |
Why?
|
| Hematologic Neoplasms | 25 | 2022 | 1870 | 1.490 |
Why?
|
| Multiple Myeloma | 21 | 2022 | 2138 | 1.370 |
Why?
|
| Leukemia, Myeloid, Acute | 37 | 2022 | 6915 | 1.310 |
Why?
|
| Transplantation, Autologous | 35 | 2022 | 1914 | 1.290 |
Why?
|
| Cyclophosphamide | 20 | 2024 | 3001 | 1.220 |
Why?
|
| Myelodysplastic Syndromes | 23 | 2021 | 2979 | 1.170 |
Why?
|
| Stem Cell Transplantation | 18 | 2021 | 1360 | 1.160 |
Why?
|
| Melphalan | 20 | 2020 | 834 | 1.150 |
Why?
|
| Vidarabine | 20 | 2022 | 1341 | 1.150 |
Why?
|
| Busulfan | 18 | 2022 | 764 | 1.070 |
Why?
|
| Cord Blood Stem Cell Transplantation | 10 | 2019 | 362 | 1.060 |
Why?
|
| Bone Marrow Transplantation | 13 | 2021 | 1581 | 1.000 |
Why?
|
| Unrelated Donors | 12 | 2023 | 304 | 1.000 |
Why?
|
| Histocompatibility Testing | 16 | 2023 | 447 | 0.970 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 5 | 2018 | 216 | 0.870 |
Why?
|
| Abortion, Induced | 1 | 2022 | 91 | 0.810 |
Why?
|
| Middle Aged | 143 | 2023 | 86204 | 0.790 |
Why?
|
| Adult | 133 | 2024 | 77950 | 0.760 |
Why?
|
| HLA Antigens | 8 | 2021 | 546 | 0.720 |
Why?
|
| Myeloablative Agonists | 11 | 2019 | 384 | 0.710 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 25 | 2022 | 15862 | 0.650 |
Why?
|
| Tacrolimus | 9 | 2022 | 335 | 0.640 |
Why?
|
| Allografts | 17 | 2019 | 650 | 0.640 |
Why?
|
| Transplantation, Haploidentical | 7 | 2022 | 125 | 0.610 |
Why?
|
| Humans | 190 | 2024 | 261506 | 0.600 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 7 | 2023 | 1664 | 0.590 |
Why?
|
| Cytomegalovirus Infections | 5 | 2019 | 462 | 0.590 |
Why?
|
| Aged | 98 | 2024 | 70117 | 0.590 |
Why?
|
| Recurrence | 30 | 2024 | 4758 | 0.580 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 12 | 2021 | 2796 | 0.570 |
Why?
|
| Adolescent | 60 | 2024 | 31252 | 0.570 |
Why?
|
| Female | 132 | 2022 | 141928 | 0.560 |
Why?
|
| Transplantation Chimera | 7 | 2015 | 155 | 0.560 |
Why?
|
| Disease-Free Survival | 35 | 2020 | 10001 | 0.550 |
Why?
|
| Young Adult | 57 | 2021 | 21445 | 0.550 |
Why?
|
| Male | 124 | 2022 | 123000 | 0.530 |
Why?
|
| Immunosuppressive Agents | 10 | 2021 | 1375 | 0.500 |
Why?
|
| Retrospective Studies | 63 | 2024 | 37905 | 0.500 |
Why?
|
| Survival Rate | 35 | 2021 | 12221 | 0.480 |
Why?
|
| Treatment Outcome | 61 | 2021 | 32848 | 0.480 |
Why?
|
| Virus Activation | 5 | 2019 | 228 | 0.480 |
Why?
|
| Graft Rejection | 6 | 2021 | 834 | 0.470 |
Why?
|
| Killer Cells, Natural | 5 | 2021 | 904 | 0.470 |
Why?
|
| Remission Induction | 22 | 2021 | 3569 | 0.460 |
Why?
|
| Survival Analysis | 29 | 2018 | 9180 | 0.450 |
Why?
|
| Heterocyclic Compounds | 3 | 2022 | 119 | 0.450 |
Why?
|
| Antiviral Agents | 6 | 2019 | 1230 | 0.440 |
Why?
|
| Histocompatibility | 8 | 2022 | 168 | 0.420 |
Why?
|
| Bronchiolitis Obliterans | 2 | 2023 | 74 | 0.420 |
Why?
|
| Lymphoma | 7 | 2019 | 1467 | 0.410 |
Why?
|
| Transplant Recipients | 5 | 2020 | 324 | 0.410 |
Why?
|
| BK Virus | 3 | 2020 | 123 | 0.400 |
Why?
|
| Polyomavirus Infections | 3 | 2020 | 139 | 0.390 |
Why?
|
| Lymphocyte Depletion | 5 | 2018 | 264 | 0.390 |
Why?
|
| Hepatic Veno-Occlusive Disease | 2 | 2024 | 122 | 0.390 |
Why?
|
| Interleukin-2 | 2 | 2009 | 842 | 0.380 |
Why?
|
| Neoplasm, Residual | 7 | 2019 | 1656 | 0.370 |
Why?
|
| Adenine Nucleotides | 4 | 2016 | 351 | 0.360 |
Why?
|
| Primary Ovarian Insufficiency | 2 | 2009 | 72 | 0.340 |
Why?
|
| Arabinonucleosides | 4 | 2016 | 437 | 0.340 |
Why?
|
| Leukemia | 7 | 2017 | 1635 | 0.340 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 8 | 2016 | 2527 | 0.340 |
Why?
|
| T-Lymphocytes | 8 | 2018 | 3869 | 0.330 |
Why?
|
| Tissue Donors | 8 | 2022 | 769 | 0.320 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 4 | 2022 | 266 | 0.320 |
Why?
|
| Breast Neoplasms | 8 | 2009 | 15694 | 0.320 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2009 | 408 | 0.320 |
Why?
|
| Mycophenolic Acid | 5 | 2022 | 148 | 0.320 |
Why?
|
| Rituximab | 5 | 2021 | 1528 | 0.300 |
Why?
|
| Tumor Virus Infections | 2 | 2020 | 224 | 0.300 |
Why?
|
| Donor Selection | 3 | 2022 | 110 | 0.300 |
Why?
|
| Prognosis | 28 | 2021 | 21713 | 0.300 |
Why?
|
| Acute Disease | 13 | 2022 | 2422 | 0.290 |
Why?
|
| Central Nervous System Neoplasms | 3 | 2017 | 502 | 0.280 |
Why?
|
| Lymphoma, Non-Hodgkin | 4 | 2016 | 1039 | 0.270 |
Why?
|
| Cytomegalovirus | 2 | 2019 | 482 | 0.270 |
Why?
|
| Severity of Illness Index | 5 | 2020 | 4320 | 0.250 |
Why?
|
| Graft Survival | 7 | 2020 | 1062 | 0.250 |
Why?
|
| Age Factors | 10 | 2020 | 5377 | 0.250 |
Why?
|
| Gastrointestinal Diseases | 3 | 2018 | 589 | 0.250 |
Why?
|
| Craniospinal Irradiation | 2 | 2017 | 128 | 0.250 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 4 | 2022 | 749 | 0.250 |
Why?
|
| Health Services Accessibility | 2 | 2022 | 761 | 0.240 |
Why?
|
| Follow-Up Studies | 18 | 2021 | 14889 | 0.240 |
Why?
|
| Antigens, CD34 | 4 | 2022 | 593 | 0.240 |
Why?
|
| Antilymphocyte Serum | 5 | 2020 | 228 | 0.240 |
Why?
|
| Antigens, CD19 | 3 | 2022 | 577 | 0.240 |
Why?
|
| Risk Factors | 19 | 2024 | 17523 | 0.230 |
Why?
|
| Hodgkin Disease | 4 | 2016 | 1429 | 0.230 |
Why?
|
| Abortion, Legal | 1 | 2022 | 10 | 0.220 |
Why?
|
| Photopheresis | 2 | 2021 | 79 | 0.220 |
Why?
|
| Carmustine | 4 | 2019 | 214 | 0.210 |
Why?
|
| Brazil | 1 | 2022 | 165 | 0.210 |
Why?
|
| Respiratory Tract Infections | 2 | 2018 | 437 | 0.210 |
Why?
|
| Hormone Antagonists | 1 | 2002 | 101 | 0.210 |
Why?
|
| Hypereosinophilic Syndrome | 1 | 2002 | 89 | 0.210 |
Why?
|
| Child | 20 | 2022 | 29154 | 0.210 |
Why?
|
| Antineoplastic Agents | 10 | 2020 | 14289 | 0.210 |
Why?
|
| Neutrophils | 4 | 2019 | 835 | 0.200 |
Why?
|
| Vascular Diseases | 1 | 2024 | 246 | 0.200 |
Why?
|
| Hematopoietic Stem Cells | 3 | 2015 | 1242 | 0.200 |
Why?
|
| Chimerism | 1 | 2021 | 63 | 0.200 |
Why?
|
| Antineoplastic Agents, Alkylating | 3 | 2018 | 588 | 0.200 |
Why?
|
| Vascularized Composite Allotransplantation | 1 | 2021 | 29 | 0.200 |
Why?
|
| Blood Component Removal | 2 | 2006 | 121 | 0.200 |
Why?
|
| Hemorrhagic Disorders | 1 | 2021 | 51 | 0.190 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2006 | 3890 | 0.190 |
Why?
|
| Lymphocyte Transfusion | 4 | 2013 | 175 | 0.190 |
Why?
|
| Genes, erbB-2 | 1 | 2001 | 229 | 0.190 |
Why?
|
| Receptors, KIR | 2 | 2022 | 62 | 0.190 |
Why?
|
| Leukemia, Myeloid | 3 | 2016 | 941 | 0.190 |
Why?
|
| Graft vs Host Reaction | 2 | 1997 | 59 | 0.190 |
Why?
|
| Pentostatin | 2 | 2017 | 119 | 0.190 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2002 | 342 | 0.190 |
Why?
|
| Neoplasm Recurrence, Local | 9 | 2023 | 10035 | 0.190 |
Why?
|
| Thiotepa | 4 | 2013 | 118 | 0.190 |
Why?
|
| Bortezomib | 2 | 2019 | 543 | 0.180 |
Why?
|
| Combined Modality Therapy | 13 | 2020 | 8865 | 0.180 |
Why?
|
| Cystitis | 1 | 2021 | 107 | 0.180 |
Why?
|
| Blood Platelets | 3 | 2015 | 731 | 0.180 |
Why?
|
| Respiratory Syncytial Virus Infections | 2 | 2014 | 427 | 0.170 |
Why?
|
| HLA-DP Antigens | 1 | 2019 | 21 | 0.170 |
Why?
|
| Models, Biological | 2 | 2019 | 3254 | 0.170 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily C | 1 | 2018 | 22 | 0.170 |
Why?
|
| POEMS Syndrome | 1 | 2018 | 22 | 0.170 |
Why?
|
| Lung Transplantation | 1 | 2023 | 359 | 0.170 |
Why?
|
| Lymphoma, Follicular | 2 | 2021 | 587 | 0.170 |
Why?
|
| Immunoglobulin Light-chain Amyloidosis | 1 | 2018 | 31 | 0.160 |
Why?
|
| Incidence | 9 | 2024 | 5673 | 0.160 |
Why?
|
| Pulmonary Embolism | 1 | 2022 | 329 | 0.160 |
Why?
|
| Protein Kinase Inhibitors | 4 | 2020 | 4757 | 0.160 |
Why?
|
| Psoriasis | 1 | 2019 | 126 | 0.160 |
Why?
|
| Whole-Body Irradiation | 4 | 2019 | 307 | 0.160 |
Why?
|
| Neutropenia | 1 | 2022 | 968 | 0.160 |
Why?
|
| Latin America | 1 | 2018 | 115 | 0.160 |
Why?
|
| Chemoprevention | 1 | 2019 | 241 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2019 | 272 | 0.160 |
Why?
|
| Social Responsibility | 1 | 2018 | 92 | 0.160 |
Why?
|
| HLA-DRB1 Chains | 1 | 2018 | 82 | 0.160 |
Why?
|
| Osteoporotic Fractures | 1 | 2018 | 37 | 0.160 |
Why?
|
| Access to Information | 1 | 2018 | 65 | 0.160 |
Why?
|
| Antimetabolites, Antineoplastic | 3 | 2014 | 1299 | 0.150 |
Why?
|
| Induction Chemotherapy | 2 | 2018 | 669 | 0.150 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2019 | 402 | 0.150 |
Why?
|
| Amifostine | 1 | 2018 | 97 | 0.150 |
Why?
|
| Prospective Studies | 11 | 2024 | 12873 | 0.150 |
Why?
|
| Vincristine | 2 | 2018 | 1511 | 0.150 |
Why?
|
| Time Factors | 11 | 2021 | 12926 | 0.150 |
Why?
|
| Blood Component Transfusion | 1 | 2017 | 89 | 0.150 |
Why?
|
| Venous Thromboembolism | 1 | 2022 | 335 | 0.150 |
Why?
|
| Mortality | 2 | 2018 | 343 | 0.150 |
Why?
|
| Kaplan-Meier Estimate | 8 | 2019 | 6207 | 0.150 |
Why?
|
| Haplotypes | 5 | 2019 | 856 | 0.150 |
Why?
|
| Postoperative Care | 1 | 2020 | 739 | 0.140 |
Why?
|
| Urologic Diseases | 1 | 2016 | 78 | 0.140 |
Why?
|
| Feasibility Studies | 8 | 2020 | 2292 | 0.140 |
Why?
|
| CDC2-CDC28 Kinases | 1 | 2016 | 129 | 0.140 |
Why?
|
| Leukemia, Biphenotypic, Acute | 1 | 2016 | 52 | 0.140 |
Why?
|
| Cost of Illness | 1 | 2019 | 498 | 0.140 |
Why?
|
| Natural Killer T-Cells | 1 | 2017 | 124 | 0.140 |
Why?
|
| Prednisone | 1 | 2018 | 984 | 0.140 |
Why?
|
| Red-Cell Aplasia, Pure | 1 | 2016 | 51 | 0.140 |
Why?
|
| Risk Assessment | 8 | 2021 | 6869 | 0.140 |
Why?
|
| Deoxycytidine | 3 | 2017 | 1353 | 0.140 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2021 | 1016 | 0.130 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2019 | 273 | 0.130 |
Why?
|
| Hepatitis B, Chronic | 1 | 2017 | 137 | 0.130 |
Why?
|
| Ribavirin | 2 | 2014 | 178 | 0.130 |
Why?
|
| Chromosome Aberrations | 4 | 2018 | 1960 | 0.130 |
Why?
|
| ABO Blood-Group System | 1 | 2016 | 127 | 0.130 |
Why?
|
| Pancytopenia | 1 | 2016 | 120 | 0.130 |
Why?
|
| Bone Marrow | 3 | 2021 | 2358 | 0.130 |
Why?
|
| Fetal Blood | 2 | 2015 | 482 | 0.130 |
Why?
|
| Hepatitis B virus | 1 | 2017 | 217 | 0.130 |
Why?
|
| Fucose | 1 | 2015 | 50 | 0.130 |
Why?
|
| DNA Transposable Elements | 1 | 2016 | 222 | 0.130 |
Why?
|
| Interleukins | 1 | 2017 | 325 | 0.130 |
Why?
|
| Fusion Proteins, bcr-abl | 2 | 2010 | 1094 | 0.130 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2018 | 3552 | 0.130 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2015 | 109 | 0.130 |
Why?
|
| Isoantibodies | 1 | 2015 | 115 | 0.130 |
Why?
|
| Gastrointestinal Tract | 1 | 2017 | 324 | 0.120 |
Why?
|
| Autografts | 3 | 2023 | 165 | 0.120 |
Why?
|
| Receptors, Antigen, T-Cell | 3 | 2022 | 1146 | 0.120 |
Why?
|
| Myeloproliferative Disorders | 1 | 2021 | 767 | 0.120 |
Why?
|
| Nitrogen Mustard Compounds | 1 | 2014 | 73 | 0.120 |
Why?
|
| Kidney Transplantation | 1 | 2020 | 755 | 0.120 |
Why?
|
| Cranial Nerve Diseases | 1 | 2014 | 73 | 0.120 |
Why?
|
| Salvage Therapy | 4 | 2017 | 2054 | 0.120 |
Why?
|
| Interferon Type I | 1 | 1995 | 250 | 0.120 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2014 | 864 | 0.120 |
Why?
|
| Steroids | 3 | 2021 | 356 | 0.120 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2022 | 907 | 0.120 |
Why?
|
| Translocation, Genetic | 1 | 2019 | 1245 | 0.120 |
Why?
|
| Retreatment | 4 | 2016 | 452 | 0.120 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2022 | 1021 | 0.120 |
Why?
|
| Child, Preschool | 10 | 2017 | 16273 | 0.120 |
Why?
|
| Gene Amplification | 1 | 2016 | 731 | 0.120 |
Why?
|
| Ganciclovir | 1 | 2013 | 174 | 0.110 |
Why?
|
| Immunotherapy, Adoptive | 4 | 2022 | 1763 | 0.110 |
Why?
|
| Amyloidosis | 1 | 2015 | 176 | 0.110 |
Why?
|
| Pandemics | 1 | 2022 | 1559 | 0.110 |
Why?
|
| Propensity Score | 3 | 2021 | 750 | 0.110 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2014 | 2390 | 0.110 |
Why?
|
| Proportional Hazards Models | 5 | 2020 | 4988 | 0.110 |
Why?
|
| Aerosols | 1 | 2013 | 158 | 0.110 |
Why?
|
| Patient Selection | 2 | 2017 | 2055 | 0.110 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 1 | 2013 | 49 | 0.110 |
Why?
|
| Mucus | 2 | 2022 | 119 | 0.110 |
Why?
|
| Blood Donors | 2 | 2010 | 164 | 0.110 |
Why?
|
| Cohort Studies | 8 | 2020 | 9244 | 0.110 |
Why?
|
| Primary Myelofibrosis | 1 | 2020 | 831 | 0.100 |
Why?
|
| Case-Control Studies | 6 | 2021 | 6100 | 0.100 |
Why?
|
| Receptor, ErbB-2 | 1 | 2001 | 2518 | 0.100 |
Why?
|
| Neoplasms | 5 | 2022 | 15193 | 0.100 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2014 | 238 | 0.100 |
Why?
|
| Lung | 2 | 2023 | 3151 | 0.100 |
Why?
|
| Azacitidine | 2 | 2020 | 1149 | 0.100 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2017 | 801 | 0.100 |
Why?
|
| Lymphoma, T-Cell | 1 | 2015 | 361 | 0.100 |
Why?
|
| Critical Illness | 1 | 2017 | 714 | 0.100 |
Why?
|
| Alleles | 2 | 2015 | 2437 | 0.100 |
Why?
|
| Drug Therapy, Combination | 4 | 2022 | 2315 | 0.100 |
Why?
|
| Drug Administration Schedule | 5 | 2021 | 3472 | 0.100 |
Why?
|
| Mucins | 2 | 2022 | 285 | 0.100 |
Why?
|
| Monocytes | 1 | 1995 | 788 | 0.100 |
Why?
|
| Virus Diseases | 1 | 2015 | 398 | 0.100 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2012 | 204 | 0.100 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2003 | 2326 | 0.100 |
Why?
|
| Neoplasm Metastasis | 3 | 2009 | 5112 | 0.100 |
Why?
|
| Nephrostomy, Percutaneous | 1 | 2011 | 55 | 0.100 |
Why?
|
| Piperazines | 2 | 2010 | 2101 | 0.090 |
Why?
|
| Urinary Catheterization | 1 | 2011 | 117 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2017 | 4938 | 0.090 |
Why?
|
| Genotype | 2 | 2016 | 4109 | 0.090 |
Why?
|
| Menopause, Premature | 1 | 2009 | 17 | 0.090 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2013 | 430 | 0.090 |
Why?
|
| Genes, MHC Class I | 1 | 2009 | 46 | 0.090 |
Why?
|
| Ureteral Obstruction | 1 | 2011 | 143 | 0.090 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2020 | 2232 | 0.090 |
Why?
|
| Podophyllotoxin | 2 | 2019 | 63 | 0.090 |
Why?
|
| Vidarabine Phosphate | 1 | 2009 | 50 | 0.090 |
Why?
|
| Pregnancy | 1 | 2022 | 7573 | 0.090 |
Why?
|
| Neoplasms, Second Primary | 1 | 2018 | 1350 | 0.090 |
Why?
|
| Cardiovascular Diseases | 1 | 2022 | 2195 | 0.080 |
Why?
|
| Intensive Care Units | 1 | 2013 | 717 | 0.080 |
Why?
|
| Graft vs Tumor Effect | 2 | 2012 | 139 | 0.080 |
Why?
|
| Protein-Tyrosine Kinases | 3 | 2011 | 1756 | 0.080 |
Why?
|
| Disease Progression | 5 | 2017 | 6682 | 0.080 |
Why?
|
| Cytarabine | 4 | 2019 | 1973 | 0.080 |
Why?
|
| Immunomodulation | 1 | 2009 | 242 | 0.080 |
Why?
|
| Antibodies | 1 | 2011 | 838 | 0.080 |
Why?
|
| Antibodies, Neoplasm | 1 | 2009 | 259 | 0.080 |
Why?
|
| Inpatients | 1 | 2013 | 678 | 0.080 |
Why?
|
| Maintenance Chemotherapy | 2 | 2019 | 202 | 0.080 |
Why?
|
| Ferritins | 2 | 2021 | 151 | 0.080 |
Why?
|
| Infertility, Female | 1 | 2009 | 217 | 0.080 |
Why?
|
| Risk | 3 | 2017 | 1972 | 0.080 |
Why?
|
| Multivariate Analysis | 4 | 2017 | 4298 | 0.080 |
Why?
|
| Philadelphia Chromosome | 1 | 2011 | 793 | 0.080 |
Why?
|
| Mutation | 5 | 2018 | 15179 | 0.070 |
Why?
|
| Hepatitis B | 1 | 2010 | 258 | 0.070 |
Why?
|
| Leukocyte Count | 1 | 2008 | 684 | 0.070 |
Why?
|
| Pyrimidines | 2 | 2010 | 3518 | 0.070 |
Why?
|
| Immunocompromised Host | 1 | 2011 | 698 | 0.070 |
Why?
|
| Hepacivirus | 1 | 2009 | 397 | 0.070 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2015 | 5178 | 0.070 |
Why?
|
| Lymphocytes | 1 | 2010 | 1234 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 3 | 2009 | 4367 | 0.060 |
Why?
|
| Skin Neoplasms | 1 | 2021 | 4654 | 0.060 |
Why?
|
| Predictive Value of Tests | 3 | 2018 | 4892 | 0.060 |
Why?
|
| Patient Education as Topic | 1 | 2009 | 748 | 0.060 |
Why?
|
| Preoperative Period | 2 | 2017 | 344 | 0.060 |
Why?
|
| Benzylamines | 2 | 2015 | 105 | 0.060 |
Why?
|
| Alkylating Agents | 1 | 2024 | 78 | 0.060 |
Why?
|
| Survivors | 1 | 2009 | 1031 | 0.060 |
Why?
|
| Cytogenetic Analysis | 2 | 2016 | 568 | 0.060 |
Why?
|
| Hypertension | 1 | 2013 | 1503 | 0.060 |
Why?
|
| Verrucomicrobia | 1 | 2022 | 26 | 0.060 |
Why?
|
| Antigen-Presenting Cells | 2 | 2016 | 284 | 0.060 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2009 | 713 | 0.060 |
Why?
|
| Xylose | 1 | 2022 | 19 | 0.060 |
Why?
|
| Prevalence | 2 | 2013 | 3260 | 0.060 |
Why?
|
| Propionates | 1 | 2022 | 71 | 0.060 |
Why?
|
| Bacteroides | 1 | 2022 | 42 | 0.050 |
Why?
|
| HLA-DP beta-Chains | 1 | 2022 | 15 | 0.050 |
Why?
|
| Graft vs Leukemia Effect | 2 | 2016 | 105 | 0.050 |
Why?
|
| Carbapenems | 1 | 2022 | 62 | 0.050 |
Why?
|
| Cell Culture Techniques | 2 | 2017 | 598 | 0.050 |
Why?
|
| Texas | 3 | 2021 | 6311 | 0.050 |
Why?
|
| Databases, Factual | 2 | 2021 | 2218 | 0.050 |
Why?
|
| Lymphocyte Count | 2 | 2015 | 486 | 0.050 |
Why?
|
| Transplantation | 2 | 2013 | 56 | 0.050 |
Why?
|
| Acute Kidney Injury | 1 | 2009 | 739 | 0.050 |
Why?
|
| Y Chromosome | 2 | 2002 | 77 | 0.050 |
Why?
|
| Neoplasm Staging | 4 | 2019 | 13658 | 0.050 |
Why?
|
| Polysaccharides | 1 | 2022 | 197 | 0.050 |
Why?
|
| Lower Gastrointestinal Tract | 1 | 2020 | 29 | 0.050 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2022 | 219 | 0.050 |
Why?
|
| Cytokines | 2 | 2023 | 2809 | 0.050 |
Why?
|
| Treatment Failure | 2 | 2017 | 1391 | 0.050 |
Why?
|
| Injections, Intravenous | 2 | 2012 | 573 | 0.050 |
Why?
|
| Siblings | 1 | 2022 | 285 | 0.050 |
Why?
|
| Cardiotoxicity | 1 | 2021 | 155 | 0.050 |
Why?
|
| Aged, 80 and over | 5 | 2022 | 29902 | 0.050 |
Why?
|
| Spirometry | 1 | 2020 | 143 | 0.050 |
Why?
|
| Germinal Center | 1 | 2021 | 161 | 0.050 |
Why?
|
| Receptors, Cytokine | 1 | 2021 | 176 | 0.050 |
Why?
|
| Azithromycin | 1 | 2020 | 78 | 0.050 |
Why?
|
| Karyotyping | 2 | 2018 | 1022 | 0.050 |
Why?
|
| Central Nervous System | 1 | 2022 | 436 | 0.040 |
Why?
|
| Mothers | 1 | 2022 | 410 | 0.040 |
Why?
|
| Ascites | 1 | 2020 | 198 | 0.040 |
Why?
|
| Lymphocyte Activation | 2 | 2016 | 1688 | 0.040 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2022 | 406 | 0.040 |
Why?
|
| Methotrexate | 1 | 2022 | 999 | 0.040 |
Why?
|
| Chromosomes | 1 | 2019 | 244 | 0.040 |
Why?
|
| Transplantation Immunology | 1 | 2019 | 97 | 0.040 |
Why?
|
| Comorbidity | 2 | 2017 | 2352 | 0.040 |
Why?
|
| Plasmapheresis | 1 | 2018 | 61 | 0.040 |
Why?
|
| Immunologic Surveillance | 1 | 2018 | 60 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2023 | 810 | 0.040 |
Why?
|
| Radiation Injuries | 1 | 2005 | 1411 | 0.040 |
Why?
|
| Plasma Cells | 1 | 2018 | 192 | 0.040 |
Why?
|
| Transplantation, Isogeneic | 1 | 2017 | 56 | 0.040 |
Why?
|
| Karyotype | 1 | 2018 | 234 | 0.040 |
Why?
|
| Forecasting | 1 | 2000 | 694 | 0.040 |
Why?
|
| B-Lymphocytes | 2 | 2015 | 1294 | 0.040 |
Why?
|
| Surveys and Questionnaires | 2 | 2009 | 5687 | 0.040 |
Why?
|
| Immunity, Innate | 1 | 2021 | 677 | 0.040 |
Why?
|
| K562 Cells | 1 | 2017 | 338 | 0.040 |
Why?
|
| CD8 Antigens | 1 | 1997 | 170 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2023 | 1493 | 0.040 |
Why?
|
| Drug Evaluation | 1 | 2016 | 425 | 0.040 |
Why?
|
| Receptors, Progesterone | 1 | 2002 | 1392 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 2016 | 141 | 0.040 |
Why?
|
| Cells, Cultured | 2 | 2017 | 5637 | 0.030 |
Why?
|
| X Chromosome | 1 | 1997 | 339 | 0.030 |
Why?
|
| Myeloma Proteins | 1 | 2015 | 28 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2022 | 787 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2021 | 1021 | 0.030 |
Why?
|
| CD56 Antigen | 1 | 2016 | 83 | 0.030 |
Why?
|
| Cyclosporine | 1 | 1997 | 278 | 0.030 |
Why?
|
| Liver Failure | 1 | 2017 | 140 | 0.030 |
Why?
|
| Premedication | 1 | 2016 | 135 | 0.030 |
Why?
|
| Vomiting | 1 | 2018 | 354 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2017 | 495 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2016 | 166 | 0.030 |
Why?
|
| Methylprednisolone | 1 | 2016 | 193 | 0.030 |
Why?
|
| Nausea | 1 | 2018 | 525 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2019 | 703 | 0.030 |
Why?
|
| Histocompatibility Antigens | 1 | 2015 | 74 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2017 | 756 | 0.030 |
Why?
|
| Age Distribution | 1 | 2017 | 698 | 0.030 |
Why?
|
| Gene Dosage | 1 | 2018 | 829 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2017 | 700 | 0.030 |
Why?
|
| Imatinib Mesylate | 2 | 2010 | 1665 | 0.030 |
Why?
|
| Dendritic Cells | 1 | 2021 | 1085 | 0.030 |
Why?
|
| Proteasome Inhibitors | 1 | 2016 | 231 | 0.030 |
Why?
|
| Facial Nerve Diseases | 1 | 2014 | 21 | 0.030 |
Why?
|
| Fucosyltransferases | 1 | 2015 | 76 | 0.030 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2017 | 375 | 0.030 |
Why?
|
| E-Selectin | 1 | 2015 | 103 | 0.030 |
Why?
|
| Bone Density | 1 | 2018 | 476 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2018 | 2803 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2020 | 3251 | 0.030 |
Why?
|
| P-Selectin | 1 | 2015 | 124 | 0.030 |
Why?
|
| Diet | 1 | 2022 | 1440 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 1323 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2002 | 1818 | 0.030 |
Why?
|
| Platelet Transfusion | 1 | 2015 | 156 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2002 | 2086 | 0.030 |
Why?
|
| Monosomy | 1 | 2014 | 95 | 0.030 |
Why?
|
| Plasmids | 1 | 2016 | 837 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 1742 | 0.030 |
Why?
|
| Bendamustine Hydrochloride | 1 | 2014 | 107 | 0.030 |
Why?
|
| Protons | 1 | 2017 | 473 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2016 | 829 | 0.030 |
Why?
|
| Benzamides | 2 | 2010 | 1832 | 0.030 |
Why?
|
| Hepatitis, Chronic | 1 | 2013 | 14 | 0.030 |
Why?
|
| Reoperation | 1 | 2018 | 1382 | 0.030 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2016 | 332 | 0.030 |
Why?
|
| Diarrhea | 1 | 2018 | 686 | 0.030 |
Why?
|
| Biopsy | 2 | 2017 | 3443 | 0.030 |
Why?
|
| Models, Statistical | 1 | 2020 | 1171 | 0.030 |
Why?
|
| Photons | 1 | 2017 | 507 | 0.030 |
Why?
|
| Optic Nerve Diseases | 1 | 2014 | 103 | 0.030 |
Why?
|
| Europe | 1 | 2015 | 649 | 0.030 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2014 | 171 | 0.030 |
Why?
|
| Graft Enhancement, Immunologic | 1 | 2012 | 37 | 0.030 |
Why?
|
| Inflammation | 1 | 2023 | 2522 | 0.030 |
Why?
|
| Recombinant Proteins | 2 | 1997 | 2927 | 0.030 |
Why?
|
| Antigens, Viral | 1 | 2015 | 471 | 0.030 |
Why?
|
| Neoadjuvant Therapy | 1 | 2006 | 4975 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2016 | 461 | 0.030 |
Why?
|
| Blood Cell Count | 1 | 2012 | 225 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2014 | 621 | 0.030 |
Why?
|
| Immunologic Factors | 1 | 2016 | 649 | 0.030 |
Why?
|
| Liver Diseases | 1 | 2017 | 574 | 0.030 |
Why?
|
| DNA Modification Methylases | 1 | 2013 | 172 | 0.030 |
Why?
|
| Cell Count | 1 | 2013 | 508 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2000 | 2594 | 0.030 |
Why?
|
| Administration, Inhalation | 1 | 2013 | 285 | 0.030 |
Why?
|
| Liver | 1 | 2002 | 2961 | 0.030 |
Why?
|
| Blast Crisis | 1 | 1995 | 557 | 0.030 |
Why?
|
| Primary Graft Dysfunction | 1 | 2012 | 34 | 0.030 |
Why?
|
| Regression Analysis | 1 | 1995 | 1546 | 0.030 |
Why?
|
| Blood Grouping and Crossmatching | 1 | 2011 | 37 | 0.030 |
Why?
|
| Dexamethasone | 1 | 2017 | 1450 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2014 | 665 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 2019 | 1879 | 0.030 |
Why?
|
| Mucositis | 1 | 2012 | 148 | 0.020 |
Why?
|
| Mice | 2 | 2022 | 34495 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2016 | 1442 | 0.020 |
Why?
|
| Consolidation Chemotherapy | 1 | 2012 | 155 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2012 | 660 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2017 | 1274 | 0.020 |
Why?
|
| Bone Marrow Cells | 1 | 1995 | 943 | 0.020 |
Why?
|
| Haploidy | 1 | 2010 | 40 | 0.020 |
Why?
|
| CD28 Antigens | 1 | 2012 | 202 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 2011 | 334 | 0.020 |
Why?
|
| CD3 Complex | 1 | 2012 | 314 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2016 | 2231 | 0.020 |
Why?
|
| Critical Care | 1 | 2017 | 770 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 1995 | 1681 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2017 | 3203 | 0.020 |
Why?
|
| Algorithms | 1 | 2022 | 3890 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2001 | 7548 | 0.020 |
Why?
|
| Patient Safety | 1 | 2016 | 649 | 0.020 |
Why?
|
| Animals | 3 | 2022 | 59536 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2014 | 2307 | 0.020 |
Why?
|
| Antigens, CD | 1 | 1995 | 1385 | 0.020 |
Why?
|
| Hospitalization | 1 | 2019 | 2083 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 6009 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2022 | 2992 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2016 | 3033 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2017 | 3005 | 0.020 |
Why?
|
| Catalytic Domain | 1 | 2010 | 303 | 0.020 |
Why?
|
| Infant | 2 | 2015 | 13310 | 0.020 |
Why?
|
| Cause of Death | 1 | 2012 | 752 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2012 | 1382 | 0.020 |
Why?
|
| Rabbits | 1 | 2010 | 957 | 0.020 |
Why?
|
| Attitude to Death | 1 | 2009 | 100 | 0.020 |
Why?
|
| Alemtuzumab | 1 | 2009 | 198 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2012 | 1544 | 0.020 |
Why?
|
| Genetic Therapy | 1 | 2016 | 1616 | 0.020 |
Why?
|
| Fear | 1 | 2009 | 254 | 0.020 |
Why?
|
| Lung Diseases | 1 | 2013 | 717 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2010 | 1487 | 0.020 |
Why?
|
| Disease Management | 1 | 2013 | 1052 | 0.020 |
Why?
|
| Cell Movement | 1 | 2015 | 2466 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2010 | 1313 | 0.020 |
Why?
|
| Biomarkers | 1 | 2018 | 5047 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2013 | 1467 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2017 | 2819 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2012 | 1555 | 0.020 |
Why?
|
| Attitude to Health | 1 | 2009 | 465 | 0.020 |
Why?
|
| Glomerular Filtration Rate | 1 | 2009 | 602 | 0.020 |
Why?
|
| Research Design | 1 | 2013 | 1544 | 0.020 |
Why?
|
| Coronary Artery Disease | 1 | 2013 | 1011 | 0.020 |
Why?
|
| Bone Neoplasms | 1 | 1998 | 2576 | 0.020 |
Why?
|
| Chronic Disease | 2 | 2004 | 1819 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2013 | 1054 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2017 | 7226 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2014 | 2669 | 0.010 |
Why?
|
| United States | 1 | 2021 | 15433 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 2009 | 915 | 0.010 |
Why?
|
| Digestive System | 1 | 2002 | 114 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 1998 | 4557 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2009 | 3842 | 0.010 |
Why?
|
| Medical Oncology | 1 | 2009 | 1423 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2009 | 2359 | 0.010 |
Why?
|
| Filgrastim | 1 | 1997 | 191 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2016 | 10331 | 0.010 |
Why?
|
| Skin | 1 | 2002 | 1259 | 0.010 |
Why?
|
| Cladribine | 1 | 1997 | 233 | 0.010 |
Why?
|
| Bone Marrow Diseases | 1 | 1997 | 177 | 0.010 |
Why?
|
| Chimera | 1 | 1995 | 145 | 0.010 |
Why?
|
| Quality of Life | 1 | 2009 | 4532 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2010 | 14551 | 0.010 |
Why?
|
| Idarubicin | 1 | 1997 | 446 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2004 | 3719 | 0.010 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 1995 | 1586 | 0.000 |
Why?
|